Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
4(40%)
Results Posted
100%(1 trials)
Terminated
2(20%)

Phase Distribution

Ph phase_1
2
20%
Ph phase_2
8
80%

Phase Distribution

2

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
8(80.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

16.7%

1 of 6 finished

Non-Completion Rate

83.3%

5 ended early

Currently Active

4

trials recruiting

Total Trials

10

all time

Status Distribution
Active(4)
Completed(1)
Terminated(5)

Detailed Status

Withdrawn3
Active, not recruiting3
Terminated2
Recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
4
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (20.0%)
Phase 28 (80.0%)

Trials by Status

recruiting110%
completed110%
terminated220%
withdrawn330%
active_not_recruiting330%

Recent Activity

4 active trials
Showing 5 of 10
active_not_recruitingphase_2

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

NCT05077800
recruitingphase_1

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

NCT06896188
terminatedphase_2

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

NCT05239182
terminatedphase_1

9-ING-41 in Pediatric Patients With Refractory Malignancies.

NCT04239092
active_not_recruitingphase_2

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

NCT05010629
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT05077800Phase 2

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Active Not Recruiting
NCT06896188Phase 1

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Recruiting
NCT05239182Phase 2

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Terminated
NCT04239092Phase 1

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Terminated
NCT05010629Phase 2

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Active Not Recruiting
NCT03678883Phase 2

9-ING-41 in Patients with Advanced Cancers

Active Not Recruiting
NCT04218071Phase 2

Actuate 1901: 9-ING-41 in Myelofibrosis

Completed
NCT04832438Phase 2

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Withdrawn
NCT05116800Phase 2

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Withdrawn
NCT04906876Phase 2

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Withdrawn

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10